{"id":832827,"date":"2025-04-02T07:48:18","date_gmt":"2025-04-02T11:48:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/"},"modified":"2025-04-02T07:48:18","modified_gmt":"2025-04-02T11:48:18","slug":"aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/","title":{"rendered":"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors"},"content":{"rendered":"
\n

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company\u2019s Board of Directors, effective March 31, 2025.<\/p>\n

\u201cI am pleased to welcome Teresa to our Board of Directors,\u201d said\u00a0Elisabet de\u00a0los Pinos, Chief Executive Officer of\u00a0Aura Biosciences. \u201cShe is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology.\u201d<\/p>\n

\u201cI am excited to join Aura\u2019s Board of Directors as the Company works to develop novel therapies in areas of high unmet medical need,\u201d said Ms. Bitetti. \u201cI look forward to collaborating with the Aura team as they continue to grow as an innovative global oncology company and work to fulfill their mission of transforming patients\u2019 lives.\u201d<\/p>\n

Ms. Bitetti is currently the President of the Global Oncology Business Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic, and hematological cancers. In this role, Ms. Bitetti leads all aspects of Takeda\u2019s multi-billion-dollar oncology business, with major markets in the US, Europe, and Japan. Before joining Takeda, Ms. Bitetti was Senior Vice President and Head of Worldwide Oncology Commercialization at Bristol Myers Squibb (BMS). She held leadership roles of increasing responsibility at BMS, including in infectious diseases and neuroscience. She served as Senior Vice President and Head of U.S. Oncology, President and General Manager of BMS Canada, and Worldwide Head of BMS Virology. Prior to BMS, Ms. Bitetti was part of the Capital Markets Group at Mobil Oil Corporation, overseeing the investment of Mobil\u2019s worldwide pension assets. In addition to her role at Takeda, Ms. Bitetti serves on the Board of Directors for Osmol Therapeutics, which is focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy. Ms. Bitetti earned her MBA from the Darden School of Business at the University of Virginia and her BA from Wellesley College.<\/p>\n

\n About\u00a0Aura Biosciences<\/strong>\n <\/p>\n

Aura Biosciences\u00a0is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer.\u00a0Aura Biosciences\u00a0is headquartered in\u00a0Boston, MA.\u00a0Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients. For more information, visit\u00a0aurabiosciences.com<\/a>. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cseeks,\u201d \u201cendeavor,\u201d \u201cpotential,\u201d \u201ccontinue\u201d or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include express or implied statements regarding Aura\u2019s future expectations, plans and prospects, including, without limitation, statements regarding the therapeutic potential of bel-sar for the treatment of multiple cancers; statements regarding Aura\u2019s plans and expectations for its ongoing and future clinical trials of bel-sar in multiple oncology indications; statements regarding Aura\u2019s plans to advance its clinical pipeline; statements regarding achieving Aura\u2019s goal to transform patients\u2019 lives; and statements regarding Aura\u2019s expectations for the estimated patient populations and related market opportunities for bel-sar.<\/p>\n

The forward-looking statements in this press release are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Aura\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of Aura\u2019s preclinical and clinical trials may not be predictive of future results in connection with future clinical trials; the risk that early or interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials; the risk that governmental authorities may disagree with Aura\u2019s clinical trial designs, even where Aura has obtained agreement with governmental authorities on the design of such trials, such as the Phase 3 special protocol assessment agreement with the U.S. Food and Drug Administration; whether Aura will receive regulatory approvals to conduct trials or to market products; whether Aura\u2019s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; Aura\u2019s ongoing and planned preclinical activities; and Aura\u2019s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials. These risks, uncertainties and other factors include those risks and uncertainties described under the heading \u201cRisk Factors\u201d in Aura\u2019s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the\u00a0United States Securities and Exchange Commission\u00a0(SEC) and in subsequent filings made by Aura with the\u00a0SEC, which are available on the SEC\u2019s website at\u00a0www.sec.gov<\/a>. Except as required by law, Aura disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Aura\u2019s current expectations and speak only as of the date hereof and no representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.<\/p>\n

\n Investor and Media Contact:<\/strong>\n <\/p>\n

Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company\u2019s Board of Directors, effective March 31, 2025. \u201cI am pleased to welcome Teresa to our Board of Directors,\u201d said\u00a0Elisabet de\u00a0los Pinos, Chief Executive Officer of\u00a0Aura Biosciences. \u201cShe is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology.\u201d \u201cI am excited to join Aura\u2019s Board of Directors as the Company works to develop novel therapies in areas of high unmet medical … <\/p>\n

Continue reading “Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832827","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, April 02, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company\u2019s Board of Directors, effective March 31, 2025. \u201cI am pleased to welcome Teresa to our Board of Directors,\u201d said\u00a0Elisabet de\u00a0los Pinos, Chief Executive Officer of\u00a0Aura Biosciences. \u201cShe is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology.\u201d \u201cI am excited to join Aura\u2019s Board of Directors as the Company works to develop novel therapies in areas of high unmet medical … Continue reading "Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T11:48:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors\",\"datePublished\":\"2025-04-02T11:48:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/\"},\"wordCount\":1009,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/\",\"name\":\"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==\",\"datePublished\":\"2025-04-02T11:48:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Market Newsdesk","og_description":"BOSTON, April 02, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company\u2019s Board of Directors, effective March 31, 2025. \u201cI am pleased to welcome Teresa to our Board of Directors,\u201d said\u00a0Elisabet de\u00a0los Pinos, Chief Executive Officer of\u00a0Aura Biosciences. \u201cShe is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology.\u201d \u201cI am excited to join Aura\u2019s Board of Directors as the Company works to develop novel therapies in areas of high unmet medical … Continue reading \"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T11:48:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors","datePublished":"2025-04-02T11:48:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/"},"wordCount":1009,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/","name":"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==","datePublished":"2025-04-02T11:48:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTA2NCM2ODQ2MDI5IzUwMDEyNDI2MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832827"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832827\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}